Sector News

Novartis buys pain drug firm Spinifex for $200 mln upfront

June 29, 2015
Life sciences
Swiss drugmaker Novartis AG boosted its presence in pain management on Monday by agreeing to buy U.S.-Australian biotech firm Spinifex Pharmaceuticals, the companies said in separate statements on Monday.
 
Spinifex said Novartis was paying $200 million upfront and Spinifex shareholders could get further payments based on clinical development and regulatory milestones. The transaction is expected to close in the second half of this year, pending regulatory approval.
 
The deal gives Novartis access to Spinifex’s experimental neuropathic pain drug EMA401, which showed positive mid-stage Phase II clinical trial results in the treating post-herpetic neuralgia (PHN), a painful condition some people get after shingles.
 
Importantly, the results published in The Lancet medical journal last year showed no central nervous system side effects or any serious adverse events.
 
Chronic neuropathic pain, caused by nerve problems, is a relatively common condition, afflicting up to 7-8 percent of the adult population, but current treatment options are limited and can be problematic.
 
Because EMA401 acts outside the blood-brain barrier it can avoid common side effects such as dizziness or confusion seen with painkillers affecting the central nervous system.
 
Novartis plans to continue the development of EMA401 and intends to start Phase IIb clinical trials in patients with PHN or another condition called painful diabetic neuropathy, which is caused by diabetes.
 
“Neuropathic pain is a chronic and debilitating condition with high unmet need. EMA401 could provide a novel, differentiated treatment approach,” said David Epstein, head of Novartis Pharmaceuticals.
 
The acquisition is small by the standards of Novartis but it highlights the Swiss group’s drive to expand its pipeline of new medicines at a time of growing investor confidence in the potential of new medicines across the drugs sector.
 
The Basel-based drugmaker is in a strong position relative to its peers thanks to recent advances with new drugs, including the widely anticipated heart failure medicine LCZ696 and a recently launched psoriasis injection called Cosentyx.
 
These should buffer it from cheaper copycat competition to older drugs.
 
Established in 2005 and based in Stamford, Connecticut and Melbourne, Australia, Spinifex is backed by venture capital groups including Novo A/S, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and the University of Queensland.
 
Deutsche Bank advised Spinifex on the sale.
 
(Reporting by Ben Hirchler and Michael Shields; Editing by Kenneth Maxwell and Mark Potter)

comments closed

Related News

September 25, 2022

Teva CEO Schultz likely won’t renew employment contract next year: reports

Life sciences

Over the weekend, Teva revealed plans to finalize its $4.35 billion national opioid settlement by the end of the year and start paying up in 2023, possibly under the helm of a new CEO as Kåre Schultz added he will not renew his CEO contract come November 2023.

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.